查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1714780

全球干细胞治疗市场按治疗类型、细胞来源、最终用户、应用、治疗领域划分——预测至 2025 年至 2030 年

Stem Cell Therapy Market by Therapy Type, Cell Source, End User, Application, Therapeutic Areas - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2023 年干细胞治疗市值将达到 39.1 亿美元，到 2024 年将以 14.27% 的复合年增长率增长至 44.5 亿美元，到 2030 年将达到 99.5 亿美元。

主要市场统计数据
基准年2023年 39.1亿美元
预计2024年 44.5亿美元
预测年份 2030 99.5亿美元
复合年增长率（%） 14.27%

干细胞治疗是现代医学中最有前景的前沿领域之一，为再生医学和疾病管理开闢了新的途径。这个创新领域利用干细胞的独特特性来修復受损组织、恢復功能并为传统治疗失败的患者带来希望。近年来，对干细胞基础生物学的广泛研究为从退化性疾病到急性损伤等各种疾病的突破性治疗方法铺平了道路。

细胞分离技术、培养方法和基因组分析的不断改进不仅提高了这些治疗方法的安全性和有效性，而且拓宽了它们的潜在应用。随着科学界和监管机构更加紧密地合作建立框架和通讯协定，将干细胞技术纳入主流医疗保健变得越来越可行。本介绍为更广泛的讨论奠定了基础，即新兴趋势和技术进步如何重塑医疗保健格局并开创个人化和再生医学的新时代。

透过进行伙伴关係以及保持强有力的临床检验，干细胞治疗市场有望改变曾经被认为遥不可及的临床实践和患者结果。

改变干细胞治疗市场

近年来，在科学快速进步和市场动态的推动下，干细胞治疗领域发生了重大变化。尖端生物技术的整合促进了从实验疗法到临床核准治疗方法的转变，并重新定义了不同医学学科的治疗策略。总的来说，细胞重编程、改善培养条件和精准医疗的创新方法正在促成模式转移，个人化医疗正成为实际的现实。

这项进步以对干细胞行为更深入的科学理解为基础，使研究人员能够克服先前在细胞活力和分化方面的限制。研究和临床试验强调了利用多种细胞来源的重要性，包括异体干细胞、诱导性多功能干细胞和周产期干细胞。

严格的监管途径和技术进步的出现继续为相关人员提供信心。经济考量、资金筹措机会和策略合作正在进一步加快该领域的创新步伐。市场驱动因素的整合将使产业更具弹性、资料主导，并能够透过再生医学来应对复杂的医疗保健挑战。

干细胞治疗的全面市场细分洞察

了解市场区隔的细微差别对于驾驭复杂的干细胞治疗生态系统至关重要。市场分析受到多种细分因素的驱动，这些因素量化了治疗方法和研究应用的多样性。主要细分之一是基于治疗类型，从而可以透过同种异体和自体移植方法对市场进行评估。无论干细胞来自捐赠者或患者自身，每种治疗方法都有其独特的优势，可以影响安全性、有效性和个人化治疗方法。

第二个重要方面是基于细胞来源的研究。本研究将探讨成体干细胞、胚胎干细胞、诱导性多功能干细胞和周产期干细胞，并着重于每种细胞的治疗潜力和限制。成体干细胞的分析研究正受到越来越多的关注，特别是透过对造血干细胞、间质干细胞和神经干细胞的研究。类似地，将透过评估周产期干细胞来自羊水、胎盘和脐带的来源来进行仔细检查。这种详细的分类提供了对每种细胞类型的相对优点和潜在临床应用的深入了解。

市场根据最终用户细分，例如学术和研究机构、生物技术和製药公司以及医院和专科诊所。这种细分反映了对研究创新、治疗发展和以患者为中心的护理模式的不同需求。此外，按应用细分突显了干细胞疗法在药物发现和开发、再生医学、组织工程等领域的应用。另一个细分领域则专注于治疗领域，心血管疾病、血液学、肌肉骨骼疾病、神经系统疾病和肿瘤学是再生疗法的主要目标。这种多方面的分析不仅强调了干细胞研究的应用广度，也强调了解决特定医学挑战所需的个人化方法。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球老化和对干细胞治疗潜力的认识不断提高
      • 政府措施和有利的法规结构正在刺激干细胞研究的进步
      • 慢性病的增多推动了对先进干细胞疗法的需求。
    • 限制因素
      • 干细胞治疗的高成本限制了患者和医疗保健提供者获得治疗的机会
    • 机会
      • 增加公共和私人对研发活动的投资
      • 基于细胞的技术的进步正在提高干细胞治疗的功效和适用性。
    • 任务
      • 了解干细胞治疗相关的各种监管环境
      • 围绕干细胞使用的伦理问题和公众认知
  • 市场区隔分析
    • 治疗类型：自体免疫疾病的治疗越来越广泛，以最大限度地降低免疫排斥和感染疾病传播的风险。
    • 细胞来源：神经干细胞增殖的重要性在于它们能够分化成中枢神经系统内的各种细胞类型
    • 最终用户：生物技术和製药公司越来越多地采用干细胞疗法来治疗神经退化性疾病疾病和心血管疾病
    • 应用：疾病建模能力将增加药物发现和开发中的应用
    • 治疗领域：干细胞疗法透过心臟修復和再生对心血管疾病的显着益处
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 干细胞治疗市场（依治疗类型）

  • 顺势疗法
  • 自体移植治疗

第七章 干细胞治疗市场 Cell Source

  • 成体干细胞
    • 造血干细胞
    • 间质干细胞
    • 神经干细胞
  • 胚胎干细胞
  • 诱导多功能细胞
  • 周产期干细胞
    • 羊水干细胞
    • 胎盘干细胞
    • 脐带干细胞

第 8 章 干细胞治疗市场（依最终使用者）

  • 学术研究所
  • 生物技术和製药公司
  • 医院和专科诊所

第九章 干细胞治疗市场：依应用

  • 药物研发
  • 再生医学
  • 组织工程

第 10 章 干细胞治疗市场（依治疗领域）

  • 心血管疾病
  • 血液学
  • 肌肉骨骼疾病
  • 神经系统疾病
  • 肿瘤学

第 11 章：美洲干细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区干细胞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲干细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Beike Biotechnology Co., Ltd.
  • BrainStorm Cell Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • CellProthera SAS
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Garuda Therapeutics
  • Holostem Terapie Avanzate Srl
  • Jasper Therapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Juvena Therapeutics Inc.
  • Kangstem Biotech Co., Ltd.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Lonza Group AG
  • Medeze Group
  • Merck KGaA
  • Mesoblast Ltd.
  • Novo Nordisk A/S
  • Plasticell
  • ReNeuron Group PLC
  • SQZ Biotechnologies Company by Stemcell Technologies
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • US Stem Cell Inc
  • Umoja Biopharma
  • Vericel Corporation
Product Code: MRR-431752EA49AD

The Stem Cell Therapy Market was valued at USD 3.91 billion in 2023 and is projected to grow to USD 4.45 billion in 2024, with a CAGR of 14.27%, reaching USD 9.95 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 3.91 billion
Estimated Year [2024] USD 4.45 billion
Forecast Year [2030] USD 9.95 billion
CAGR (%) 14.27%

Stem cell therapy represents one of the most promising frontiers in modern medicine, opening new avenues for regenerative treatments and disease management. This innovative field harnesses the distinctive properties of stem cells to repair damaged tissues, restore functionality, and offer patients hope where conventional treatments may fall short. In recent years, extensive research has driven a better understanding of the underlying biology of stem cells, paving the way for breakthrough therapies that target a range of conditions from degenerative disorders to acute injuries.

The continuous refinement in cell isolation techniques, culture methods, and genomic profiling has not only increased the safety and efficacy of these therapies but also expanded their potential applications. As the scientific community and regulatory bodies work more closely to establish frameworks and protocols, the integration of stem cell technology into mainstream healthcare is becoming increasingly feasible. This introduction sets the stage for a broader discussion on how emerging trends and technological advances are reshaping the landscape, ushering in a new era of personalized and regenerative medicine.

By embracing interdisciplinary research, fostering public and private partnerships, and maintaining robust clinical validations, the stem cell therapy market is poised to transform both clinical practices and patient outcomes in a manner that was once considered out of reach.

Transformative Shifts in the Stem Cell Therapy Landscape

Recent years have been marked by transformative shifts in the landscape of stem cell therapy, driven by rapid scientific advancements and evolving market dynamics. The integration of state-of-the-art biotechnologies has facilitated the progression from experimental phases to clinically approved treatments, thereby redefining therapeutic strategies across diverse medical disciplines. Innovative methods in cell reprogramming, enhanced culture conditions, and precision medicine have collectively contributed to a paradigm shift where personalized care is becoming a tangible reality.

This evolution is underpinned by a deeper scientific understanding of stem cell behavior that has enabled researchers to overcome previous limitations related to cell viability and differentiation. Research and clinical trials have not only highlighted the therapeutic potential of both allogeneic and autologous approaches but have also underscored the importance of harnessing varied cell sources such as adult, embryonic, induced pluripotent, and perinatal stem cells.

The emergence of rigorous regulatory paths, combined with technological advancements, continues to instill confidence in stakeholders. Economic considerations, funding opportunities, and strategic collaborations are further accelerating the pace of innovation in this sector. As market drivers converge, the result is an industry that is more resilient, data-driven, and capable of addressing complex healthcare challenges through regenerative medicine.

Comprehensive Market Segmentation Insights in Stem Cell Therapy

Understanding the nuances of market segmentation is critical to navigating the complex ecosystem of stem cell therapy. The market analysis is driven by multiple segmentation factors that quantify the diversity in treatment modalities and research applications. One primary segmentation is based on therapy type, where the market is evaluable both under allogeneic and autologous approaches. Each method brings distinct advantages, whether deriving stem cells from donors or patients themselves, thereby influencing safety, efficacy, and personalized treatment options.

A second pivotal dimension is the investigation based on cell source. The research examines adult stem cells, embryonic stem cells, induced pluripotent stem cells, and perinatal stem cells to discern their therapeutic potential and limitations. Adult stem cells receive further analytical attention, particularly through the study of hematopoietic, mesenchymal, and neural stem cells, each contributing unique properties that influence treatment outcomes. Similarly, perinatal stem cells are scrutinized by evaluating amniotic fluid, placental, and umbilical cord sources. This granular breakdown provides insights into the relative merits and clinical applicability of each cell type.

The market is further divided according to end user segments-academic and research institutions, biotechnology and pharmaceutical companies, and hospitals and specialty clinics. Such segmentation reflects the varying demands for research innovation, therapy development, and patient-centered treatment models. Additionally, the application-based segmentation emphasizes the utilization of stem cell therapies in drug discovery and development, regenerative medicine, and tissue engineering. Another segmentation area focuses on therapeutic areas, where cardiovascular diseases, hematology, musculoskeletal disorders, neurological disorders, and oncology are the primary targets of regenerative interventions. This multidimensional analysis not only highlights the expansive application of stem cell research but also underscores the tailored approaches that are required to address specific medical challenges.

Based on Therapy Type, market is studied across Allogeneic Therapy and Autologous Therapy.

Based on Cell Source, market is studied across Adult Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells, and Perinatal Stem Cells. The Adult Stem Cells is further studied across Hematopoietic Stem Cells, Mesenchymal Stem Cells, and Neural Stem Cells. The Perinatal Stem Cells is further studied across Amniotic Fluid Stem Cells, Placental Stem Cells, and Umbilical Cord Stem Cells.

Based on End User, market is studied across Academic & Research Institutions, Biotechnology & Pharmaceutical Companies, and Hospitals & Specialty Clinics.

Based on Application, market is studied across Drug Discovery and Development, Regenerative Medicine, and Tissue Engineering.

Based on Therapeutic Areas, market is studied across Cardiovascular Diseases, Hematology, Musculoskeletal Disorders, Neurological Disorders, and Oncology.

Global Regional Dynamics in the Stem Cell Therapy Market

Regional dynamics play a crucial role in mapping the global landscape of stem cell therapy. Market trends and regulatory approvals exhibit distinct patterns across different regions. In the Americas, robust investment in biomedical research and well-established healthcare infrastructures are significant drivers for the adoption of advanced stem cell therapies. The region's diverse population and proactive public-private partnerships have spurred rapid development and clinical trials that continue to influence global standards.

Meanwhile, in regions encompassing Europe, the Middle East, and Africa, a blend of tradition and innovation is pushing forward progressive healthcare agendas. Researchers and policymakers in these areas are increasingly focused on developing localized therapies that address region-specific health challenges while aligning with international protocols. The strengthening of regulatory frameworks in these regions further supports the safe and effective integration of stem cell therapies into routine clinical practice.

In the Asia-Pacific region, rapid economic growth combined with a significant increase in research funding has positioned the area as a burgeoning hub for biotechnology and regenerative medicine. Driven by expansive clinical research, technological adoption, and a rising middle-class demand for advanced healthcare solutions, the Asia-Pacific markets are progressively adopting novel stem cell therapies. This tripartite regional overview provides a comprehensive understanding of how local trends, regulatory environments, and economic factors interplay to shape the global market landscape of stem cell therapy.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Steering Stem Cell Therapy Advancements

Numerous pioneering companies are at the vanguard of driving advancements in the stem cell therapy space. Industry leaders such as Anterogen Co., Ltd. and Astellas Pharma Inc. are continuously adopting innovative approaches to developing breakthrough therapies. These companies, along with emerging innovators like Beike Biotechnology Co., Ltd. and BrainStorm Cell Therapeutics Inc., are instrumental in translating cutting-edge research into clinically effective solutions. Notable pharmaceutical giants like Bristol-Myers Squibb Company and Kite Pharma, Inc. under Gilead Sciences, Inc. have also contributed significantly by leveraging their extensive research networks and global resources to propel stem cell therapies forward.

Other prominent market players, including CellProthera SAS, Fate Therapeutics, Inc., and Gamida Cell Ltd., are recognized for their focus on enhancing the differentiation processes and ensuring consistent quality across therapeutic applications. Companies such as Garuda Therapeutics and Holostem Terapie Avanzate S.r.l. have further diversified the landscape by exploring novel cell sources and addressing unmet clinical needs. Jasper Therapeutics, Inc. and JCR Pharmaceuticals Co., Ltd. are continuously pushing the envelope for clinical innovation, while Juvena Therapeutics Inc., Kangstem Biotech Co., Ltd., and Lonza Group AG play critical roles by ensuring the scalability and reliability of stem cell production.

In addition, organizations like Medeze Group, Merck KGaA, and Mesoblast Ltd. are investing in research and development to establish next-generation treatment protocols. Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, and SQZ Biotechnologies Company by Stemcell Technologies are leveraging the latest in cellular engineering to expand therapeutic frontiers. Finally, companies such as Takara Bio Inc., Thermo Fisher Scientific Inc., U.S. Stem Cell Inc., Umoja Biopharma, and Vericel Corporation round out the comprehensive list of key players whose consistent innovation and market presence are setting the pace for the future of stem cell therapy. Each of these companies not only contributes technological expertise and clinical experience but also serves as a benchmark for excellence in advancing regenerative medicine.

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Astellas Pharma Inc., Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera SAS, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech Co., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lonza Group AG, Medeze Group, Merck KGaA, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, SQZ Biotechnologies Company by Stemcell Technologies, Takara Bio Inc., Thermo Fisher Scientific Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation. Strategic Recommendations for Maximizing Growth in Stem Cell Therapy

In an evolving industry characterized by rapid advancements and regulatory complexities, industry leaders must adopt strategic measures to sustain growth in the field of stem cell therapy. First, it is essential to continuously invest in research and development to not only improve the therapeutic efficiency of existing modalities but also to discover novel approaches that could address emerging clinical challenges. Maintaining strong collaborations with academic research institutions and global biotechnological networks will enable companies to stay at the forefront of innovation.

Second, companies should prioritize the implementation of rigorous quality control measures and standardized manufacturing processes. This approach will ensure safety, enhance scalability, and promote regulatory compliance throughout the entire production lifecycle. Embracing digital transformations-such as integrating data analytics and artificial intelligence into research pipelines-could provide sharper insights into clinical outcomes and operational efficiencies.

Third, industry stakeholders must tailor their strategies to the unique demands of different regional markets. Customized solutions that account for local regulatory frameworks and market maturity can significantly enhance market penetration and clinical acceptance. It is equally important to build strong, trust-based relationships with healthcare providers by offering continuous education, technical support, and transparent communication regarding the benefits and limitations of various therapies.

Finally, proactive engagement with regulatory bodies is crucial. Keeping abreast of policy changes and participating in shaping future guidelines can preempt regulatory challenges and facilitate smoother market entry. By combining innovation, operational excellence, and strategic regional focus, companies can effectively navigate the competitive landscape and drive sustained growth in the therapeutic domain.

Executive Summary Conclusion: The Future of Stem Cell Therapy

As the stem cell therapy market matures, the convergence of technological breakthroughs, evolving regulatory landscapes, and comprehensive segmentation strategies has painted a promising outlook for the future of regenerative medicine. The journey from laboratory innovation to clinical application is now marked by transformative shifts that are reshaping the standards of care in diverse therapeutic areas. From the rigorous analysis of therapy types and cell sources to the dynamic influence of regional markets and the relentless pursuit of technological excellence by key industry players, every facet of this ecosystem has contributed to building a robust, scalable, and patient-centric therapeutic paradigm.

The continuous evolution of therapeutic strategies coupled with strategic collaborations is further cementing the role of stem cell therapy as an essential component in modern medical practice. As clinical trials yield increasingly positive results and regulatory pathways become more clearly defined, the potential to address complex health issues with precision medicine grows stronger every day. Stakeholders are now presented with a unique opportunity to not only capitalize on these advancements but also to drive the next wave of clinical innovations that could redefine treatment protocols across boundaries.

In summary, the strategic foresight, collaborative efforts, and unwavering commitment to excellence in research and development are setting the stage for breakthroughs that will transform patient care globally. The industry is poised on the brink of a new era, one that promises to deliver enhanced therapeutic outcomes and improved quality of life for patients worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging global population and awareness about the therapeutic potential of stem cells
      • 5.1.1.2. Government initiatives and favorable regulatory frameworks are promoting stem cell research advancement
      • 5.1.1.3. Growing prevalence of chronic diseases is fueling the need for advanced stem cell therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with stem cell therapy limit accessibility for both patients and providers
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing public and private investment in research and development activities
      • 5.1.3.2. Advancements in cell-based technologies are enhancing the efficacy and applications of stem cell therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating the varying regulatory landscape for stem cell therapies
      • 5.1.4.2. Ethical concerns and public perception surrounding the use of stem cells
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Growing applications of autologous therapy owing to minimizing the risk of immune rejection and transmission of infectious diseases
    • 5.2.2. Cell Source: Proliferating significance of neural stem cells due to the ability to differentiate into various cell types within the central nervous system
    • 5.2.3. End User: Increasing adoption of stem cell therapy in biotechnology & pharmaceutical companies for addressing neurodegenerative diseases and cardiovascular disorders
    • 5.2.4. Application: Rising applications in drug discovery and development owing to their ability to model diseases
    • 5.2.5. Therapeutic Areas: Significant benefits of stem cell therapy in cardiovascular diseases owing to cardiac repair and regeneration
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Stem Cell Therapy Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Allogeneic Therapy
  • 6.3. Autologous Therapy

7. Stem Cell Therapy Market, by Cell Source

  • 7.1. Introduction
  • 7.2. Adult Stem Cells
    • 7.2.1. Hematopoietic Stem Cells
    • 7.2.2. Mesenchymal Stem Cells
    • 7.2.3. Neural Stem Cells
  • 7.3. Embryonic Stem Cells
  • 7.4. Induced Pluripotent Stem Cells
  • 7.5. Perinatal Stem Cells
    • 7.5.1. Amniotic Fluid Stem Cells
    • 7.5.2. Placental Stem Cells
    • 7.5.3. Umbilical Cord Stem Cells

8. Stem Cell Therapy Market, by End User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutions
  • 8.3. Biotechnology & Pharmaceutical Companies
  • 8.4. Hospitals & Specialty Clinics

9. Stem Cell Therapy Market, by Application

  • 9.1. Introduction
  • 9.2. Drug Discovery and Development
  • 9.3. Regenerative Medicine
  • 9.4. Tissue Engineering

10. Stem Cell Therapy Market, by Therapeutic Areas

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Hematology
  • 10.4. Musculoskeletal Disorders
  • 10.5. Neurological Disorders
  • 10.6. Oncology

11. Americas Stem Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Stem Cell Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Stem Cell Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. REGiMMUNE and Kiji Therapeutics unite to advance Treg-focused stem cell therapies
    • 14.3.2. Evotec and Novo Nordisk partnership advances stem cell therapy innovations for scalable solutions
    • 14.3.3. Collaboration between Somite Therapeutics and OmniaBio Inc. aims to revolutionize stem cell therapy with AI-driven approaches for Duchenne muscular dystrophy
    • 14.3.4. Bioserve India's launch of advanced stem cell products propels innovative research and therapies in India's regenerative medicine landscape
    • 14.3.5. Cell BioEngines secures USD 2 million funding to advance 'off-the-shelf' hematopoietic stem cell therapies and initiate multicenter clinical trials
    • 14.3.6. OrganaBio revolutionizes advanced therapy development with on-demand GMP-compliant hematopoietic stem cells
    • 14.3.7. FDA expands approval for CARVYKTI as the first BCMA-targeted therapy advancing multiple myeloma treatment
    • 14.3.8. Strategic partnership accelerates stem cell therapy development through streamlined collaboration
    • 14.3.9. Fujifilm to Invest USD 200 Million in Cell Therapy Production
    • 14.3.10. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
    • 14.3.11. Merger between Selecta Biosciences and Cartesian Therapeutics pioneers RNA cell therapy advancements
    • 14.3.12. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
    • 14.3.13. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
    • 14.3.14. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
    • 14.3.15. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
    • 14.3.16. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
    • 14.3.17. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
    • 14.3.18. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
    • 14.3.19. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
    • 14.3.20. Novo Nordisk to Expand R&D Presence in Greater Boston Area
    • 14.3.21. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
    • 14.3.22. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
    • 14.3.23. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Kite Pharma, Inc. by Gilead Sciences, Inc.
    • 14.4.2. JCR Pharmaceuticals Co., Ltd.
    • 14.4.3. Novo Nordisk A/S
    • 14.4.4. Astellas Pharma Inc.

Companies Mentioned

  • 1. Anterogen Co., Ltd.
  • 2. Astellas Pharma Inc.
  • 3. Beike Biotechnology Co., Ltd.
  • 4. BrainStorm Cell Therapeutics Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. CellProthera SAS
  • 7. Fate Therapeutics, Inc.
  • 8. Gamida Cell Ltd.
  • 9. Garuda Therapeutics
  • 10. Holostem Terapie Avanzate S.r.l.
  • 11. Jasper Therapeutics, Inc.
  • 12. JCR Pharmaceuticals Co., Ltd.
  • 13. Juvena Therapeutics Inc.
  • 14. Kangstem Biotech Co., Ltd.
  • 15. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 16. Lonza Group AG
  • 17. Medeze Group
  • 18. Merck KGaA
  • 19. Mesoblast Ltd.
  • 20. Novo Nordisk A/S
  • 21. Plasticell
  • 22. ReNeuron Group PLC
  • 23. SQZ Biotechnologies Company by Stemcell Technologies
  • 24. Takara Bio Inc.
  • 25. Thermo Fisher Scientific Inc.
  • 26. U.S. Stem Cell Inc
  • 27. Umoja Biopharma
  • 28. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. STEM CELL THERAPY MARKET MULTI-CURRENCY
  • FIGURE 2. STEM CELL THERAPY MARKET MULTI-LANGUAGE
  • FIGURE 3. STEM CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 4. STEM CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. STEM CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 328. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 329. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023